Lucid Diagnostics Inc. Share Price & Technical Analysis
LUCD · $1.00 (-2.91%)
Healthcare / Medical Devices
$1.00
-2.91%
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the…
Price chart
Seasonality
Jun has 1 positive and 3 negative years (last 5 years shown)
0% return in Jun, -13% avg return in past 3 year Jun month.
-5% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | 17% | -21% | 0% | -9% | 0% | – | – | – | – | – | – | -5% |
| 25 | 25% | 67% | 0% | -20% | 8% | -15% | -9% | 30% | -23% | 20% | -8% | 10% | 83% |
| 24 | 0% | -14% | -33% | 0% | 0% | -11% | 0% | 0% | 0% | 25% | 11% | -20% | -43% |
| 23 | -7% | 8% | 0% | 0% | 7% | -12% | 0% | 7% | -25% | 8% | 15% | -7% | -6% |
| 22 | -41% | 16% | -8% | -38% | 0% | 5% | 26% | -27% | -32% | 19% | -5% | -22% | -108% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$198.39M
P/E ratio
—
52W high
$1.63
52W low
$0.90
Volume
8,13,666
Beta
1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Lucid Diagnostics Inc. share price today?
- Lucid Diagnostics Inc. (LUCD) last traded around $1.00 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LUCD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LUCD. Download the app for real-time alerts.
- How can I analyze Lucid Diagnostics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.